NewAmsterdam Pharma Company N.V Financials
This page shows NewAmsterdam Pharma Company N.V (NAMS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 5 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores
NewAmsterdam Pharma Company N.V has an operating margin of 1002.9%, meaning the company retains $1003 of operating profit per $100 of revenue. This strong profitability earns a score of 100/100, reflecting efficient cost management and pricing power. This is up from -386.9% the prior year.
NewAmsterdam Pharma Company N.V's revenue declined 100% year-over-year, from $45.6M to $23K. This contraction results in a growth score of 0/100.
NewAmsterdam Pharma Company N.V carries a low D/E ratio of 0.13, meaning only $0.13 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 7.88, NewAmsterdam Pharma Company N.V holds $7.88 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.
NewAmsterdam Pharma Company N.V converts 655.6% of revenue into free cash flow ($148K). This strong cash generation earns a score of 100/100.
NewAmsterdam Pharma Company N.V earns a strong 29.8% return on equity (ROE), meaning it generates $30 of profit for every $100 of shareholders' equity. This efficient capital use earns a returns score of 100/100.
NewAmsterdam Pharma Company N.V scores 27445.96, well above the 2.99 safe threshold. The score is driven primarily by a large market capitalization ($3.9B) relative to total liabilities ($86K). This indicates low bankruptcy risk based on profitability, leverage, and asset efficiency.
NewAmsterdam Pharma Company N.V passes 3 of 9 financial strength tests. 3 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), neither operating efficiency signal passes.
For every $1 of reported earnings, NewAmsterdam Pharma Company N.V generates $0.73 in operating cash flow ($148K OCF vs $204K net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.
Key Financial Metrics
NewAmsterdam Pharma Company N.V generated $23K in revenue in fiscal year 2025. This represents a decrease of 100.0% from the prior year.
NewAmsterdam Pharma Company N.V's EBITDA was $226K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 100.1% from the prior year.
NewAmsterdam Pharma Company N.V generated $148K in free cash flow in fiscal year 2025, representing cash available after capex. This represents an increase of 100.1% from the prior year.
NewAmsterdam Pharma Company N.V reported $204K in net income in fiscal year 2025. This represents an increase of 100.1% from the prior year.
NewAmsterdam Pharma Company N.V earned $1.72 per diluted share (EPS) in fiscal year 2025. This represents an increase of 167.2% from the prior year.
NewAmsterdam Pharma Company N.V held $490K in cash against $0 in long-term debt as of fiscal year 2025.
NewAmsterdam Pharma Company N.V had 115M shares outstanding in fiscal year 2025. This represents an increase of 6.4% from the prior year.
NewAmsterdam Pharma Company N.V's operating margin was 1002.9% in fiscal year 2025, reflecting core business profitability. This is up 1389.8 percentage points from the prior year.
NewAmsterdam Pharma Company N.V's net profit margin was 905.7% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1436.0 percentage points from the prior year.
NewAmsterdam Pharma Company N.V's ROE was 29.8% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
NewAmsterdam Pharma Company N.V invested $142K in research and development in fiscal year 2025. This represents a decrease of 99.9% from the prior year.
NewAmsterdam Pharma Company N.V invested $246 in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 100.0% from the prior year.
NAMS Income Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $348K-98.2% | $19.1M+542.9% | $3.0M-76.7% | $12.8M+460.4% | $2.3M+62.7% | $1.4M+74.5% | $803K-72.7% | $2.9M |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | $31.0M+12.6% | $27.5M-38.5% | $44.8M+28.2% | $34.9M-9.1% | $38.4M-9.5% | $42.4M+2.8% | $41.3M-4.8% | $43.4M |
| SG&A Expenses | $24.5M-10.1% | $27.3M+0.4% | $27.2M+28.6% | $21.1M+28.1% | $16.5M+14.0% | $14.5M+36.5% | $10.6M+16.0% | $9.1M |
| Operating Income | -$55.1M-54.7% | -$35.6M+48.3% | -$68.9M-59.4% | -$43.2M+17.8% | -$52.6M+5.2% | -$55.5M-8.6% | -$51.1M-3.1% | -$49.6M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax | N/A | N/A | N/A | -$1K | N/A | N/A | N/A | N/A |
| Net Income | -$72.0M-314.7% | -$17.4M+56.1% | -$39.5M+57.1% | -$92.2M-136.3% | -$39.0M+58.4% | -$93.8M-89.4% | -$49.5M-5.0% | -$47.1M |
| EPS (Diluted) | $-0.61-306.7% | $-0.15+55.9% | $-0.34+62.6% | $-0.91-122.0% | $-0.41+61.3% | $-1.06-76.7% | $-0.60-5.3% | $-0.57 |
NAMS Balance Sheet
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $786.4M-3.5% | $815.1M-0.4% | $818.4M-5.3% | $864.6M+93.6% | $446.7M-8.6% | $488.5M+40.7% | $347.1M | N/A |
| Current Assets | $732.3M-4.9% | $769.9M-5.8% | $817.3M-5.3% | $863.4M+93.9% | $445.4M-8.7% | $487.8M+40.7% | $346.8M | N/A |
| Cash & Equivalents | $538.4M-4.5% | $563.9M-24.7% | $748.4M-3.0% | $771.7M+79.2% | $430.7M-10.5% | $481.1M+41.3% | $340.4M | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $58.4M+59.4% | $36.6M-10.8% | $41.0M-61.7% | $107.1M+80.8% | $59.3M-22.7% | $76.7M+30.6% | $58.7M | N/A |
| Current Liabilities | $58.3M+59.6% | $36.5M-10.8% | $40.9M-61.7% | $106.9M+136.0% | $45.3M-24.1% | $59.7M+19.7% | $49.9M | N/A |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $728.1M-6.5% | $778.5M+0.1% | $777.4M+2.6% | $757.5M+95.5% | $387.4M-5.9% | $411.8M+42.8% | $288.4M-13.1% | $331.8M |
| Retained Earnings | -$687.5M-11.7% | -$615.5M-2.9% | -$598.1M-7.1% | -$558.6M-24.2% | -$449.7M-9.5% | -$410.7M-29.6% | -$317.0M | N/A |
NAMS Cash Flow Statement
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$32.8M+13.0% | -$37.7M-3.3% | -$36.5M+2.7% | -$37.5M+30.6% | -$54.0M+1.1% | -$54.6M-65.1% | -$33.1M+29.6% | -$47.0M |
| Capital Expenditures | $42K-52.3% | $88K+450.0% | $16K+433.3% | $3K-98.6% | $209K-45.7% | $385K+12733.3% | $3K-66.7% | $9K |
| Free Cash Flow | -$32.8M+13.1% | -$37.8M-3.5% | -$36.5M+2.7% | -$37.5M+30.8% | -$54.2M+1.5% | -$55.0M-66.2% | -$33.1M+29.6% | -$47.0M |
| Investing Cash Flow | $2.5M+101.6% | -$159.1M-5673.9% | $2.9M+104.6% | -$62.2M-29650.7% | -$209K+45.7% | -$385K-12733.3% | -$3K+66.7% | -$9K |
| Financing Cash Flow | $5.9M+72.0% | $3.4M-47.5% | $6.5M-98.6% | $456.6M+9702.7% | $4.7M-97.6% | $198.2M | $0-100.0% | $186K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
NAMS Financial Ratios
| Metric | Q3'25 | Q2'25 | Q1'25 | Q3'24 | Q2'24 | Q1'24 | Q4'23 | Q3'23 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | -15845.7%-15659.6pp | -186.1%+2128.3pp | -2314.5%-1976.0pp | -338.5%+1968.5pp | -2306.9%+1653.2pp | -3960.2%+2400.2pp | -6360.4%-4675.3pp | -1685.1% |
| Net Margin | -20691.1%-20600.4pp | -90.7%+1236.6pp | -1327.3%-605.6pp | -721.7%+989.9pp | -1711.6%+4981.3pp | -6692.9%-529.1pp | -6163.8%-4561.1pp | -1602.6% |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -9.2%-7.0pp | -2.1%+2.7pp | -4.8%+5.8pp | -10.7%-1.9pp | -8.7%+10.5pp | -19.2%-4.9pp | -14.3% | N/A |
| Current Ratio | 12.57-8.5 | 21.08+1.1 | 19.98+11.9 | 8.08-1.8 | 9.83+1.7 | 8.17+1.2 | 6.95 | N/A |
| Debt-to-Equity | 0.08+0.0 | 0.050.0 | 0.05-0.1 | 0.14-0.0 | 0.15-0.0 | 0.19-0.0 | 0.20 | N/A |
| FCF Margin | -9428.4%-9231.2pp | -197.2%+1027.9pp | -1225.1%-931.6pp | -293.5%+2084.2pp | -2377.7%+1547.1pp | -3924.8%+194.3pp | -4119.2%-2521.6pp | -1597.6% |
Similar Companies
Frequently Asked Questions
What is NewAmsterdam Pharma Company N.V's annual revenue?
NewAmsterdam Pharma Company N.V (NAMS) reported $23K in total revenue for fiscal year 2025. This represents a -100.0% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
How fast is NewAmsterdam Pharma Company N.V's revenue growing?
NewAmsterdam Pharma Company N.V (NAMS) revenue declined by 100% year-over-year, from $45.6M to $23K in fiscal year 2025.
Is NewAmsterdam Pharma Company N.V profitable?
Yes, NewAmsterdam Pharma Company N.V (NAMS) reported a net income of $204K in fiscal year 2025, with a net profit margin of 905.7%.
What is NewAmsterdam Pharma Company N.V's earnings per share (EPS)?
NewAmsterdam Pharma Company N.V (NAMS) reported diluted earnings per share of $1.72 for fiscal year 2025. This represents a 167.2% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.
What is NewAmsterdam Pharma Company N.V's EBITDA?
NewAmsterdam Pharma Company N.V (NAMS) had EBITDA of $226K in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is NewAmsterdam Pharma Company N.V's operating margin?
NewAmsterdam Pharma Company N.V (NAMS) had an operating margin of 1002.9% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is NewAmsterdam Pharma Company N.V's net profit margin?
NewAmsterdam Pharma Company N.V (NAMS) had a net profit margin of 905.7% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is NewAmsterdam Pharma Company N.V's return on equity (ROE)?
NewAmsterdam Pharma Company N.V (NAMS) has a return on equity of 29.8% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is NewAmsterdam Pharma Company N.V's free cash flow?
NewAmsterdam Pharma Company N.V (NAMS) generated $148K in free cash flow during fiscal year 2025. This represents a 100.1% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is NewAmsterdam Pharma Company N.V's operating cash flow?
NewAmsterdam Pharma Company N.V (NAMS) generated $148K in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are NewAmsterdam Pharma Company N.V's total assets?
NewAmsterdam Pharma Company N.V (NAMS) had $769K in total assets as of fiscal year 2025, including both current and long-term assets.
What are NewAmsterdam Pharma Company N.V's capital expenditures?
NewAmsterdam Pharma Company N.V (NAMS) invested $246 in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does NewAmsterdam Pharma Company N.V spend on research and development?
NewAmsterdam Pharma Company N.V (NAMS) invested $142K in research and development during fiscal year 2025.
How many shares does NewAmsterdam Pharma Company N.V have outstanding?
NewAmsterdam Pharma Company N.V (NAMS) had 115M shares outstanding as of fiscal year 2025.
What is NewAmsterdam Pharma Company N.V's current ratio?
NewAmsterdam Pharma Company N.V (NAMS) had a current ratio of 7.88 as of fiscal year 2025, which is generally considered healthy.
What is NewAmsterdam Pharma Company N.V's debt-to-equity ratio?
NewAmsterdam Pharma Company N.V (NAMS) had a debt-to-equity ratio of 0.13 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is NewAmsterdam Pharma Company N.V's return on assets (ROA)?
NewAmsterdam Pharma Company N.V (NAMS) had a return on assets of 26.5% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is NewAmsterdam Pharma Company N.V's Altman Z-Score?
NewAmsterdam Pharma Company N.V (NAMS) has an Altman Z-Score of 27445.96, placing it in the Safe Zone (low bankruptcy risk). The Z-Score combines five financial ratios—working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets—to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is NewAmsterdam Pharma Company N.V's Piotroski F-Score?
NewAmsterdam Pharma Company N.V (NAMS) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are NewAmsterdam Pharma Company N.V's earnings high quality?
NewAmsterdam Pharma Company N.V (NAMS) has an earnings quality ratio of 0.73x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is NewAmsterdam Pharma Company N.V?
NewAmsterdam Pharma Company N.V (NAMS) scores 83 out of 100 on our Financial Profile, indicating strong overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.